BioEurope Spring 2014

ImmuSmol will be in Turin on March 10-12 2014 for BioEurope Spring to present its pipeline of therapeutic monoclonal antibodies targeting small molecules.

CEO Alban Bessede will participate to the partnering event with the aim of establishing early partnerships for 2 R&D programs:

• Personalized cancer immunotherapy program IS001: Based on a monoclonal antibody targeting a pathometabolite involved in cancer immune escape, IS001 aims at restoring anti-cancer immune response. Latest in vivo results and diagnostic data will be presented.

• Neurodegenerative disease biotherapy IS002: ImmuSmol developed a small molecule mAb aimed at preventing neuronal cell death. Following promising in vitro results, ImmuSmol will be seeking an industrial partner to support in vivo testing.

For more information about ImmuSmol’s R&D pipeline, please contact us.